Karuna Scores Major Schizophrenia Win And Shares Break Out To Record High - Investor's Business Daily

Karuna Therapeutics easily beat expectations for its midstage test in schizophrenia.

Karuna Therapeutics (KRTX) topped expectations Monday in a study of its schizophrenia treatment, and the biotech stock soared to a record high. XOn the stock market today, biotech stock Karuna catap… [+2478 chars]

full article...